ABUS
Arbutus Biopharma Corp
NASDAQ: ABUS · HEALTHCARE · BIOTECHNOLOGY
$5.12
+0.00% today
Updated 2026-09-11
Market cap
$1.01B
P/E ratio
6.48
P/S ratio
5.58x
EPS (TTM)
$0.79
Dividend yield
—
52W range
$4 – $5
Volume
3.1M
WallStSmart proprietary scores
43
out of 100
Grade: D
Sell
Investment rating
2.7
Growth
F7.0
Quality
B+8.0
Profitability
A6.7
Valuation
B4/9
Piotroski F-Score
Moderate
-17.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$5.51
+7.62%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 84.20% — above average
+ ROE 59.16% — strong efficiency
+ Debt/equity 0.01x — low leverage
Risks
- Altman Z -17.77 — distress zone
- Negative free cash flow $-11.97M
- Revenue declining -90.60% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $39.02M | $18.14M | $6.17M | $14.08M | $181.72M |
| Net income | $-69.46M | $-72.85M | $-69.92M | $-33.50M | $-5.14M |
| EPS | — | — | — | — | $0.79 |
| Free cash flow | $-35.87M | $-86.94M | $-65.03M | $-39.64M | $-11.97M |
| Profit margin | -178.01% | -401.57% | -1,133.04% | -237.88% | 84.20% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-08 | SAWHNEY, ROGER | Buy | 78,800 | — |
| 2026-06-08 | BEARDSLEY, ROBERT A | Buy | 78,800 | — |
| 2026-02-02 | NGUYEN, TUAN | Buy | 188,400 | — |
Peer comparison
Smart narrative
Arbutus Biopharma Corp trades at $5.12. representing a P/E of 6.48x trailing earnings. Our Smart Value Score of 43/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -17.77, it sits in the distress. TTM revenue stands at $181.72M. with profit margins at 84.20%.
Frequently asked questions
What is Arbutus Biopharma Corp's stock price?
Arbutus Biopharma Corp (ABUS) trades at $5.12, on a P/E of 6.5x and a P/S of 5.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Arbutus Biopharma Corp overvalued?
Arbutus Biopharma Corp carries a Smart Value Score of 43/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Arbutus Biopharma Corp (ABUS)?
The 12-month analyst consensus target is $5.51, about 7.6% above the current $5.12. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Arbutus Biopharma Corp's revenue?
Arbutus Biopharma Corp's trailing twelve-month revenue is $181.72M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Arbutus Biopharma Corp's Altman Z-Score is -17.77, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.58x
ROE59.16%
Beta0.62
50D MA$4.77
200D MA$4.50
Shares out0.20B
Float0.12B
Short ratio—
Avg volume3.1M
Performance
1 week-0.38%
1 month+20.98%
3 months+13.82%
YTD+7.90%
1 year—
3 years—
5 years—